To determine whether predischarge event recording (PDER) can accurately identify preterm infants with resolving apnea of prematurity (AOP) at risk for postdischarge complications.
Apnea of prematurity (AOP) is a common diagnosis in the premature infant, occurring in up to 85% of infants of Ͻ34 weeks' gestation. 1 Timing of discharge for infants with AOP in a safe and expedient manner is a challenge faced by many neonatologists. Criteria for discharge of these infants may include an apnea-free interval, 2 usage of medications (methylxanthines), 3, 4 gestational age (GA) at birth, or corrected age at discharge.
Documented event recording has been used to evaluate the compliance of monitor usage at home 5, 6 and to document efficacy of treatment; 7, 8 in addition, documented event recording has been shown to result in a shorter duration of home monitoring compared with a nonrecording monitor. 9 We use predischarge recordings as a tool for determining the need for home apnea monitoring at hospital discharge.
Event-recording apnea monitors record cardiorespiratory waveforms with pulse oximetry; the user sets the parameters that define an event. [5] [6] [7] [8] [9] [10] [11] [12] [13] For example, in-hospital "test" parameters in our institution record apneas lasting for Ͼ10 seconds and heart rates of Ͻ90 beats per minute. Smith and Hoy 14 reported a positive correlation between an abnormal predischarge event recording (PDER) performed for 1 week and continued apneas at home. We sought to determine whether a 24-hour PDER in preterm infants treated with caffeine could accurately identify infants who are at greater risk of an adverse outcome [15] [16] [17] [18] [19] [20] (apparent life-threatening event [ALTE], rehospitalization, and death).
METHODS
The medical records of all preterm infants followed by the Infant Apnea Program at University Medical Center and Hospital at Stony Brook during the period of January 1, 1996 to January 13, 1999 were reviewed retrospectively. Only those infants discharged with caffeine citrate were included. Informed consent was not deemed necessary, as the management was routine practice and within the acceptable standard of care. The GA of the infants was assessed at the time of birth by means of Ballard assessment and maternal dating; the final assignment was taken as that assigned by the neonatal attending.
AOP was diagnosed clinically by the neonatologist on service as periods of bradycardia and desaturations associated with any duration of apnea. The decision to treat with caffeine was made by the attending on service, and the threshold to treat may have varied among attendings.
All infants with resolving AOP treated with caffeine that were deemed ready for discharge by the neonatal attending were studied. The discharge criteria for these infants during this time period were uniform: Infants had to be nipple feeding at Յ22 cal/oz formula and growing, had to be able to maintain body temperature in a bassinet, had to be free of stimulation for apneas for 1 week, and had to have a Original Article
PDER performed by the Apnea Program. All infants discharged with caffeine had levels of at least 15 mg/dl. A Smart Monitor (Respironics 970S or 970SE, Healthdyne, Marietta, GA) was used for PDER for Ն24 hours. The monitor was set to record a 1-minute window triggered by a central apnea of 10 seconds or a heart rate of Ͻ90 beats per minute. The electrocardiogram, instantaneous heart rate, oxygen saturation, pulse rate from pulse oximetry, and respiratory impedance were recorded. A normal event recording was defined as the absence of any prolonged apnea (Ͼ20 seconds) and prolonged bradycardia (heart rate of Ͻ80 beats per minute for Ͼ5 seconds) at rest. The attending neonatologist decided for home monitoring based on the recommendations of the Infant Apnea Program after interpretation of the recording.
The recommendations of the Infant Apnea Program for home monitoring of infants with resolving AOP on caffeine were uniform. Infants with a normal PDER were to be discharged without a monitor as long as they were free of stimulation for 1 week. Infants with an abnormal PDER were to be discharged with an apnea monitor or were to remain hospitalized for continued observation and treatment. All infants discharged with monitors had monitor downloads monthly or when the memory filled. The same criteria for normal versus abnormal recordings were used after discharge. All of the patient recordings were prospectively reviewed by one of us (J. D. D.).
Infants with a normal PDER were compared with infants with an abnormal PDER. The following demographic data were compared: birth weight, discharge weight, GA at birth, corrected age at discharge, length of stay (LOS), medications at the time of discharge, and duration of caffeine treatment. The primary outcome variable was an adverse outcome (apnea-related emergency department [ER] visit or rehospitalization, ALTE, or death). An ALTE was defined as an episode frightening to the observer that was characterized by some combination of apnea, color change, marked change in muscle tone, choking, or gagging. 21 To determine adverse outcome, parents of this group were contacted by phone or mail and questioned about the primary outcome variable of postdischarge complications: ALTEs, an apnea-related ER visit, hospital readmission, or death. The medical records of any infant rehospitalized at University Hospital were reviewed.
Differences between groups were compared by Student's t-test, Mann-Whitney rank sum test, or Fisher's Exact test. A p value of Ͻ 0.05 was considered significant. The predictive value of having a normal or abnormal event recording and postdischarge complications was determined.
RESULTS
A total of 106 infants constituted the cohort; of these infants, 74 had a normal event recording and 32 had an abnormal recording. At 6 months, 100% of the infants had follow-up data. We found no difference in birth weight, GA at birth, LOS, discharge weight, and duration of outpatient caffeine treatment between the two groups ( Table 1) .
There was no difference between groups with regard to the use of other discharge medications (H 2 -Blocker, Cisapride).
Of the 32 infants who had an abnormal PDER, there was one (1 of 32) reported death, one (1 of 32) ER visit for monitor alarms (32 weeks' gestation, 1830-gm birth weight), two (2 of 32) ALTEs, and four hospital readmissions for nonapnea-related diagnoses. These four admissions were for the diagnoses of sepsis, anemia with bronchiolitis, viral meningitis, and upper respiratory infection. Monitor downloads of these four infants at the time of hospital readmission were normal. The two infants with ALTEs presented with color changes and monitor alarms and received stimulation. Monitor downloads of these two infants were abnormal, with prolonged apneas and bradycardias. These infants were 28 and 34 weeks' gestation at birth, with birth weights of 905 gm and 2900 gm, respectively. The one infant who died was diagnosed with sudden infant death syndrome after autopsy and death scene investigation 9 days after discharge. His GA was 30 weeks with a birth weight of 1595 gm. This infant was not treated with Cisapride and was not on an apnea monitor at the time of death. No recording of this death was available. Seven other infants discharged with abnormal PDERs also had continued pathologic apneas on downloads but were asymptomatic.
Infants with normal recordings before hospital discharge had no apnea-related ER visits, ALTEs, or death. Five infants were rehospitalized during the first year of life for nonapnea-related reasons: two for bronchiolitis, one for viral syndrome, and the other two for elective surgery. Infants treated with Cisapride had no adverse outcomes or abnormal monitor downloads after discharge. The primary outcome variable of postdischarge complications is shown in Table 2 . Infants with an abnormal PDER had a significantly greater frequency of postdischarge complications ( p Ͻ 0.05, power ϭ 0.7). The positive predictive value of having a normal PDER and have no apnea-related ER visit, hospital readmission, ALTE, or death was 100%. The positive predictive value of having an abnormal PDER and a postdischarge complication was 12.5%.
DISCUSSION
Definitive criteria for safe discharge of the premature infant with resolving AOP remain controversial. 2 Nursing observation alone misses about half of the apnea and bradycardias when compared with the objective data of event-recording monitoring. [22] [23] [24] [25] [26] This has led some investigators 27 to recommend testing the asymptomatic preterm infant by predischarge pneumocardiogram. However, missed events by nursing observation would suggest that these events were all selfresolved in nature or that nurses simply failed to document them. Our combined approach of nursing observation plus normal event recording was predictive of no postdischarge complications.
In this study, we had a low occurrence of postdischarge complications in the total population of preterm infants with resolving AOP (just 4%). Even infants with an abnormal PDER had few postdischarge complications (Ͼ10%). Only 2 of the 32 infants with an abnormal PDER presented with ALTEs (6%), an incidence that is approximately two to three times higher than that reported in the general population. 28 These two infants had color changes and received stimulation. Infants that were not monitored may have had self-resolved apnea and bradycardia that went undetected at home. Indeed, 7 of the 32 infants with abnormal PDERs had asymptomatic pathologic apnea on download after discharge.
Most of the infants with resolving AOP on caffeine citrate from our neonatal intensive care unit are discharged before 36 weeks corrected age independent of GA at birth. This suggests that the hospital LOS can be shortened by discharging infants with methylxanthines instead of discontinuing their medication and monitoring them for some apnea-free interval.
Birth weight, GA at birth, LOS, and discharge weight were similar between our two groups. This observation suggests that infants with resolving AOP treated with caffeine who have postdischarge complications cannot be identified by GA or birth weight alone. Our results differ from those of Barrington et al., 11 who found no relationship between PDER and adverse outcome. Barrington screened every infant with a birth weight of Ͻ1250 gm, not just those with resolving AOP treated with caffeine. They defined a significant apnea as an episode lasting for Ͼ12 seconds with a 10% drop in heart rate. We studied only infants with resolving AOP with caffeine, independent of GA or birth weight, and defined significant apnea as an episode lasting for Ն20 seconds, thus describing a subpopulation of that previous report. 11 Our results suggest that infants discharged on caffeine with a normal PDER are functionally more mature than the abnormal group despite a similar corrected GA at discharge.
Discharge criteria for infants treated with medication for resolving AOP vary among institutions. Some units require that all medication be discontinued before discharge, usually followed by some apnea-free interval. Others require that all infants treated with methylxanthines be discharged with an apnea monitor. Some units discharge all of their preterm infants with home apnea monitors simply because of severe prematurity. 29 Hunt and Brouillette 30 have described their experience with 300 infants, some of whom were treated with methylxanthines after discharge without monitors after a normal pneumogram, an approach that is similar to ours. These differences in approach may depend on the philosophy of the neonatologists and on the existence of an Infant Apnea Program. 29 To date there are little data justifying the use of apnea monitors at home, due to the fact that the efficacy of these monitors has not been proven; 21, 29, 31 in addition, monitoring does not prevent sudden infant death syndrome, [32] [33] [34] [35] [36] [37] [38] [39] nor is event recording a reliable predictor of sudden infant death syndrome. In this report, the occurrence of one sudden infant death syndrome death in 106 patients is an expected finding and is probably unrelated to an abnormal PDER. Apnea monitoring is not without complications. Some of these include parental anxiety, increased risk of readmissions after discharge, and increased medical cost. 40 -44 Infants on apnea monitors will have alarms, most of which are false alarms. 5 In addition, monitored infants may succumb to the vulnerable child syndrome. Reports of patient electrocution by monitoring have disappeared as a result of the mandated Food and Drug Administration safety requirements for home medical equipment.
We conclude that the objective data from event recording help to identify a pattern of cardiorespiratory maturation and act as a supplement to the subjective nature of nursing observations. 26 Moreover, PDERs of preterm infants with resolving AOP treated with caffeine accurately identify infants at low risk for an adverse outcome. We speculate that closer follow-up of infants with abnormal PDERs may help to decrease postdischarge complications. 
